ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
2,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
3,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
4,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
4,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
5,1,Libido decreased,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
6,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
6,2,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
6,3,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
7,1,Ejaculation failure,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
8,1,Blepharospasm,Eyelid movement disorders,Ocular neuromuscular disorders,Eye,N
8,2,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
9,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,Y
10,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
11,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
12,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
13,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
14,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
15,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
16,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
16,2,Extrapyramidal disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
17,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
18,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
19,1,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
20,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
21,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
22,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
22,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
23,1,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
24,1,Extrapyramidal disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
24,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
25,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
26,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
27,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
28,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
29,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
30,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
31,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
32,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
33,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
34,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
35,1,Extrapyramidal disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
36,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
37,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
38,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
39,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
40,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
41,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
42,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
43,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
44,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
45,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
46,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
47,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
48,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
49,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
50,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
51,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
52,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
53,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
54,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
55,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
56,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
57,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
58,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
59,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
60,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
60,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
61,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
62,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
63,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
64,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
64,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
65,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
66,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
67,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
68,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
69,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
70,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
71,1,Extrapyramidal disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
71,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
72,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
73,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
73,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
74,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
74,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
75,1,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
76,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
77,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
78,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
79,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
80,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
81,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
81,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
81,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
82,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
83,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
84,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
85,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
86,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
87,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
88,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
89,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
90,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
91,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
92,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
93,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
94,1,Injection site fibrosis,Injection site reactions,Administration site reactions,Genrl,N
95,1,Injection site fibrosis,Injection site reactions,Administration site reactions,Genrl,N
96,1,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
97,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
98,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
99,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
100,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
101,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
102,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
103,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
104,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
104,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
105,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
106,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
107,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
108,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
109,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
110,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
111,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
112,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
113,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
114,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
115,1,Injection site fibrosis,Injection site reactions,Administration site reactions,Genrl,N
116,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
117,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
118,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
119,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
120,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
121,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
122,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
123,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
124,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
125,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
126,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
127,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
128,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
129,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
130,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
131,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
132,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
132,2,Libido decreased,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
133,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
134,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
135,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
136,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
137,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
138,1,Accommodation disorder,Refractive and accommodative disorders,Vision disorders,Eye,N
139,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
140,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
141,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
142,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
143,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
144,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
145,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
146,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
147,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
148,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
149,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
150,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
151,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
152,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
153,1,Alcohol intolerance,Food malabsorption and intolerance syndromes (excl sugar intolerance),Food intolerance syndromes,Metab,N
154,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
155,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
156,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
157,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
158,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
159,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
160,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
161,1,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
162,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
163,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
164,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
165,1,Hirsutism,Hypertrichoses,Skin appendage conditions,Skin,N
166,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
167,1,Infertility male,Sexual function and fertility disorders NEC,Sexual function and fertility disorders,Repro,N
168,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
169,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
170,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
171,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
172,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
173,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
174,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
175,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
176,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
177,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
178,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
179,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
180,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
181,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
182,1,Eyelid ptosis,Eyelid movement disorders,Ocular neuromuscular disorders,Eye,N
182,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
183,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
184,1,Visual field defect,Visual field disorders,Vision disorders,Eye,N
185,1,Growth retardation,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
185,2,Ventricular septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
186,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
187,1,Hyperprolactinaemia,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
188,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
189,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
190,1,Corneal opacity,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
191,1,Neuroleptic malignant syndrome,Muscle tone abnormal,Neuromuscular disorders,Nerv,Y
192,1,Hyperpyrexia,Febrile disorders,Body temperature conditions,Genrl,N
192,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
192,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
193,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
193,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
193,3,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
194,1,Injection site fibrosis,Injection site reactions,Administration site reactions,Genrl,N
195,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
195,2,Headache,Headaches NEC,Headaches,Nerv,N
196,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
196,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
197,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
198,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
198,2,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
199,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
199,2,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
200,1,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
200,2,Hypertonia,Muscle tone abnormal,Neuromuscular disorders,Nerv,N
200,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
201,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
202,1,Neuroleptic malignant syndrome,Muscle tone abnormal,Neuromuscular disorders,Nerv,N
203,1,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
203,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
203,3,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
204,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
204,2,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
205,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
205,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
206,1,Coordination abnormal,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
206,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
206,3,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
207,1,Neuroleptic malignant syndrome,Muscle tone abnormal,Neuromuscular disorders,Nerv,N
208,1,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
